Sana Biotechnology
SANA
164 hedge funds and large institutions have $258M invested in Sana Biotechnology in 2024 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 58 increasing their positions, 33 reducing their positions, and 32 closing their positions.
125% more call options, than puts
Call options by funds: $3.54M | Put options by funds: $1.57M
76% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 33
31% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 32
6% more funds holding
Funds holding: 155 → 164 (+9)
1.84% more ownership
Funds ownership: 68.94% → 70.78% (+1.8%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
60% less capital invested
Capital invested by funds: $639M → $258M (-$380M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.61M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.06M |
| 3 |
Corient Private Wealth
Miami,
Florida
|
+$2.18M |
| 4 |
Millennium Management
New York
|
+$2.01M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.26M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$1.56M |
| 3 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$1.17M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$1.11M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$1.01M |
SANA Hedge Fund Activity: Q4 2024 in Review
164 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q4 2024, worth a combined $258M — down 60% from $639M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new SANA positions and 32 closed out — a net gain of 10 holders — while 58 added to existing stakes and 33 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $5.61M. The largest seller was Vanguard Group, cutting an estimated $7.26M.
- 164 institutional investors held Sana Biotechnology (SANA) as of Q4 2024, up from 155 in Q3 2024.
- Funds reported $258M of Sana Biotechnology stock for Q4 2024, down 60% quarter-over-quarter.
- 42 funds opened new Sana Biotechnology positions in Q4 2024 and 32 closed out, a net change of +10 holders.
- The largest Sana Biotechnology buyer in Q4 2024 was Fidelity Investments, an estimated $5.61M added.
- The largest Sana Biotechnology seller in Q4 2024 was Vanguard Group, an estimated $7.26M sold.
Based on aggregated 13F filings for Q4 2024.